TAM
RXRX icon

Titleist Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Titleist Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,065
Closed -$156K – 322
2024
Q4 		$156K Sell
23,065
-15,750
-41% -$106K 0.02% 300
2024
Q3 		$256K Hold
38,815
– – 0.04% 244
2024
Q2 		$291K Sell
38,815
-6,450
-14% -$56.3K 0.04% 223
2024
Q1 		$451K Buy
45,265
+5,815
+15% +$64.8K 0.08% 165
2023
Q4 		$389K Buy
39,450
+3,700
+10% +$26.4K 0.07% 162
2023
Q3 		$273K Hold
35,750
– – 0.06% 179
2023
Q2 		$267K Hold
35,750
– – 0.05% 186
2023
Q1 		$238K Buy
+35,750
New +$284K 0.05% 188

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Titleist Asset Management's RXRX Position: Q1 2025 in Review

Titleist Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 23,065 shares — an estimated $156K sold.

Titleist Asset Management first reported a position in RXRX in Q1 2023 and held it in 8 quarters. The position peaked at $451K in Q1 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Titleist Asset Management reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Titleist Asset Management sold 23,065 Recursion Pharmaceuticals shares in Q1 2025, an estimated $156K.
  • Titleist Asset Management first reported a position in Recursion Pharmaceuticals in Q1 2023 and held it in 8 quarters.
  • Titleist Asset Management's Recursion Pharmaceuticals position peaked at $451K in Q1 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Titleist Asset Management's 13F filing for Q1 2025, filed 15 May 2025.